Semma is a privately held biotechnology company that uses stem cell-derived human islets for Type 1 diabetes treatments. It will become a separate operating subsidiary of Vertex, with CEO Bastiano Sanna joining Vertex as president of Semma. Douglas Melton, the scientific founder of Semma, will stay as chair of its scientific advisory board while guiding on research and development.
The acquisition is expected to close in Q4 subject to conditions including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Price: 181.50, Change: +1.48, Percent Change: +0.82
|Sector Update: Financial Stocks Easing Near Session ...|
|Ventas Receives All Rents for April, May from Triple...|
|Sector Update: Energy Stocks Extending Tuesday Gains|
|Chatham Lodging Trust Sees Small But Steady Improvem...|
|US Stocks Set to Close Higher as Investors Look Past...|